| Year |
Citation |
Score |
| 2023 |
O'Sullivan JA, Kohlhapp FJ, Zloza A, Plaza-Rojas L, Burke B, Dulin NO, Guevara-Patiño JA. Memory Precursors and Short-Lived Effector T cell Subsets Have Different Sensitivities to TGFβ. International Journal of Molecular Sciences. 24. PMID 36835342 DOI: 10.3390/ijms24043930 |
0.339 |
|
| 2023 |
Kohlhapp FJ, O'Sullivan JA, Moore TV, Zloza A, Guevara-Patiño JA. NKG2D signaling shifts the balance of CD8 T cells from single cytokine- to polycytokine-producing effector cells. Molecular Immunology. 155: 1-6. PMID 36634520 DOI: 10.1016/j.molimm.2022.12.013 |
0.412 |
|
| 2020 |
Geraghty T, Rajagopalan A, Aslam R, Pohlman A, Venkatesh I, Zloza A, Cimbaluk D, DeNardo DG, Gupta V. Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung Cancer. Frontiers in Oncology. 10: 748. PMID 32528880 DOI: 10.3389/Fonc.2020.00748 |
0.39 |
|
| 2019 |
Newman JH, Chesson CB, Herzog NL, Bommareddy PK, Aspromonte SM, Pepe R, Estupinian R, Aboelatta MM, Buddhadev S, Tarabichi S, Lee M, Li S, Medina DJ, Giurini EF, Gupta KH, ... ... Zloza A, et al. Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 31888983 DOI: 10.1073/Pnas.1904022116 |
0.373 |
|
| 2019 |
Bommareddy PK, Zloza A, Rabkin SD, Kaufman HL. Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. Oncoimmunology. 8: 1591875. PMID 31143509 DOI: 10.1080/2162402X.2019.1591875 |
0.457 |
|
| 2019 |
Nikolaev EV, Zloza A, Sontag ED. Immunobiochemical Reconstruction of Influenza Lung Infection-Melanoma Skin Cancer Interactions. Frontiers in Immunology. 10: 4. PMID 30745900 DOI: 10.3389/Fimmu.2019.00004 |
0.393 |
|
| 2019 |
Newman J, NeMoyer R, Zloza A, Langenfeld J. Double-Humanized Mouse Model to Study Bone Morphogenetic Protein (BMP) Signaling in Tumor Xenografts. Methods in Molecular Biology (Clifton, N.J.). 1891: 257-262. PMID 30414139 DOI: 10.1007/978-1-4939-8904-1_19 |
0.35 |
|
| 2018 |
Bommareddy PK, Aspromonte S, Zloza A, Rabkin SD, Kaufman HL. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Science Translational Medicine. 10. PMID 30541787 DOI: 10.1126/Scitranslmed.Aau0417 |
0.436 |
|
| 2018 |
Romaguera JE, Lee HJ, Tarapore R, Prabhu V, Allen J, Schalop L, Zloza A, Ok CY, Sadimin ET, Schenkel J, Badillo M, Wang M. Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment. British Journal of Haematology. PMID 29740811 DOI: 10.1111/Bjh.15271 |
0.323 |
|
| 2018 |
Newman JH, Augeri DJ, NeMoyer R, Malhotra J, Langenfeld E, Chesson CB, Dobias NS, Lee MJ, Tarabichi S, Jhawar SR, Bommareddy PK, Marshall S, Sadimin ET, Kerrigan JE, Goedken M, ... ... Zloza A, et al. Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer. Oncogene. PMID 29622797 DOI: 10.1038/S41388-018-0156-9 |
0.365 |
|
| 2018 |
Wagner J, Kline CL, Zhou L, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino JR, et al. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. The Journal of Clinical Investigation. PMID 29533922 DOI: 10.1172/Jci96711 |
0.408 |
|
| 2018 |
Mehnert JM, Silk AW, Wen Y, Lee JH, Dudek L, Jeong BS, Li J, Schenkel JM, Sadimin E, Kane M, Lin H, Shih WJ, Zloza A, Chen S, Goydos JS. A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma. Pigment Cell & Melanoma Research. PMID 29453787 DOI: 10.1111/Pcmr.12694 |
0.309 |
|
| 2018 |
Silk AW, Berman R, Coric V, Ruggiero L, Reitz AB, Shih W, Kane MP, Mehnert JM, Pelletier JC, Zloza A, Goydos JS. A phase I study to evaluate the safety of trigriluzole (BHV-4157) in combination with PD-1 blocking antibodies. Journal of Clinical Oncology. 36: TPS80-TPS80. DOI: 10.1200/Jco.2018.36.5_Suppl.Tps80 |
0.319 |
|
| 2018 |
Silk AW, LeBoeuf NR, Rabinowits G, Puzanov I, Burgess MA, Devata S, Moore D, Goydos JS, Chen HX, Kaufman H, Zloza A, Mehnert JM. A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057). Journal of Clinical Oncology. 36: TPS219-TPS219. DOI: 10.1200/Jco.2018.36.5_Suppl.Tps219 |
0.388 |
|
| 2018 |
Tarapore RS, Stein MN, Zloza A, Rodriguez L, Newman J, Cheeson C, Stogniew M, Oster W, Allen JE. Abstract 5568: Clinical immunostimulatory activity of imipridone ONC201, a selective DRD2 antagonist, in advanced solid tumor patients Cancer Research. 78: 5568-5568. DOI: 10.1158/1538-7445.Am2018-5568 |
0.387 |
|
| 2018 |
Prabhu VV, Madhukar N, Kline CLB, Tarapore R, El-Deiry W, Elemento O, Doherty F, VanEngelenburg A, Durrant J, Zloza A, Benes C, Arrillaga I, Oster W, Allen JE. Abstract A060: Targeting DRD2 dysregulation in recurrent glioblastoma with imipridone ONC201: predictive and pharmacodynamic clinical biomarker analyses Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A060 |
0.333 |
|
| 2018 |
Tarapore R, Jhawar S, Stein M, Haffty B, Zloza A, Mueller S, Zhang J, Amoroso F, Mills I, Oster W, Allen J. DDIS-16. ONC201 IN COMBINATION WITH RADIATION EXHIBITS SYNERGISTIC EFFICACY IN HIGH GRADE GLIOMAS AND OTHER ADVANCED CANCERS Neuro-Oncology. 20: vi72-vi72. DOI: 10.1093/Neuonc/Noy148.295 |
0.312 |
|
| 2017 |
Chesson CB, Zloza A. Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer. Nanomedicine (London, England). PMID 29098928 DOI: 10.2217/Nnm-2017-0254 |
0.343 |
|
| 2017 |
Jhawar SR, Thandoni A, Bommareddy PK, Hassan S, Kohlhapp FJ, Goyal S, Schenkel JM, Silk AW, Zloza A. Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies. Frontiers in Oncology. 7: 202. PMID 28955655 DOI: 10.3389/Fonc.2017.00202 |
0.388 |
|
| 2017 |
Sedhom R, Zloza A, Kohlhapp FJ, Medina D, Strair R. Magnesium alterations of graft immune cells (MAGIC). Journal of Clinical Oncology. 35: e18541-e18541. DOI: 10.1200/Jco.2017.35.15_Suppl.E18541 |
0.451 |
|
| 2017 |
Stein MN, Chan N, Silk AW, Malhotra J, Aisner J, Aiken R, Zloza A, El-Deiry WS, Newman J, Chesson C, Tarapore R, Allen JE, Oster W, Saunders T, Yu B, et al. Anticancer and immunostimulatory activity of the imipridone ONC201, a selective DRD2 antagonist, in advanced cancer patients. Journal of Clinical Oncology. 35: 2586-2586. DOI: 10.1200/Jco.2017.35.15_Suppl.2586 |
0.33 |
|
| 2017 |
Silk AW, Kaufman H, Gabrail N, Mehnert J, Bryan J, Norrell J, Medina D, Bommareddy P, Shafren D, Grose M, Zloza A. Abstract CT026: Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemicpembrolizumab inadvanced melanoma patients: Interim results of the CAPRA clinical trial Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct026 |
0.376 |
|
| 2017 |
Wagner J, Kline CL, Zhou L, Zloza A, Chesson C, Newman J, Kaufman H, Bertino J, Stein M, El-Deiry W. Abstract 124: Imipridone ONC201 promotes intra-tumoral accumulation of CD3+/NK+ cells that contribute to its anti-tumor efficacy Cancer Research. 77: 124-124. DOI: 10.1158/1538-7445.Am2017-124 |
0.423 |
|
| 2016 |
Lasfar A, Zloza A, de la Torre A, Cohen-Solal KA. IFN-λ: A New Inducer of Local Immunity against Cancer and Infections. Frontiers in Immunology. 7: 598. PMID 28018361 DOI: 10.3389/Fimmu.2016.00598 |
0.337 |
|
| 2016 |
Kohlhapp FJ, Huelsmann EJ, Lacek AT, Schenkel JM, Lusciks J, Broucek JR, Goldufsky JW, Hughes T, Zayas JP, Dolubizno H, Sowell RT, Kühner R, Burd S, Kubasiak JC, Nabatiyan A, ... ... Zloza A, et al. Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death. Cell Reports. 17: 957-965. PMID 27760326 DOI: 10.1016/J.Celrep.2016.09.068 |
0.417 |
|
| 2016 |
Zloza A, Dharmadhikari ND, Huelsmann EJ, Broucek JR, Hughes T, Kohlhapp FJ, Kaufman HL. Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma. Cancer Immunology, Immunotherapy : Cii. PMID 27757560 DOI: 10.1007/S00262-016-1916-4 |
0.411 |
|
| 2016 |
Lasfar A, Gogas H, Zloza A, Kaufman HL, Kirkwood JM. IFN-λ cancer immunotherapy: new kid on the block. Immunotherapy. 8: 877-88. PMID 27381684 DOI: 10.2217/Imt-2015-0021 |
0.304 |
|
| 2016 |
Lasfar A, de la Torre A, Abushahba W, Cohen-Solal KA, Castaneda I, Yuan Y, Reuhl K, Zloza A, Raveche E, Laskin DL, Kotenko SV. Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth. Oncotarget. PMID 27363032 DOI: 10.18632/Oncotarget.10272 |
0.309 |
|
| 2016 |
Lasfar A, Zloza A, Cohen-Solal KA. IFN-lambda therapy: current status and future perspectives. Drug Discovery Today. 21: 167-71. PMID 26552337 DOI: 10.1016/J.Drudis.2015.10.021 |
0.329 |
|
| 2015 |
Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nature Reviews. Drug Discovery. 14: 642-62. PMID 26323545 DOI: 10.1038/Nrd4663 |
0.312 |
|
| 2015 |
Kohlhapp FJ, Broucek JR, Hughes T, Huelsmann EJ, Lusciks J, Zayas JP, Dolubizno H, Fleetwood VA, Grin A, Hill GE, Poshepny JL, Nabatiyan A, Ruby CE, Snook JD, Rudra JS, ... ... Zloza A, et al. NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. Journal For Immunotherapy of Cancer. 3: 18. PMID 25992289 DOI: 10.1186/S40425-015-0063-3 |
0.42 |
|
| 2015 |
Zhang YG, Wu S, Lu R, Richards MH, Huelsmann EJ, Lacek AT, Nabatiyan A, Chen D, Al-Harthi L, Zloza A, Sun J. HIV Infection Leads to Redistribution of Leaky Claudin-2 in the Intestine of Humanized SCID IL-2R(-/-) Hu-PBMC Mice. Aids Research and Human Retroviruses. PMID 25853489 DOI: 10.1089/Aid.2014.0341 |
0.6 |
|
| 2015 |
Kohlhapp F, Huelsmann E, Rudra J, Nabatiyan A, Zloza A. Single-step nanoparticle antigen presentation system for tumor immunotherapy Journal For Immunotherapy of Cancer. 3: P319. DOI: 10.1186/2051-1426-3-S2-P319 |
0.418 |
|
| 2015 |
Kohlhapp F, Huelsmann E, Broucek J, Schenkel J, Kaufman H, Zloza A. Acute viral infection results in a PD-1-dependent loss of anti-tumor CD8+ T cell responses: implications for tumor immunotherapy Journal For Immunotherapy of Cancer. 3: P281. DOI: 10.1186/2051-1426-3-S2-P281 |
0.437 |
|
| 2014 |
Zloza A, Kim DW, Broucek J, Schenkel JM, Kaufman HL. High-dose IL-2 induces rapid albumin uptake by endothelial cells through Src-dependent caveolae-mediated endocytosis. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 34: 915-9. PMID 24963699 DOI: 10.1089/Jir.2013.0155 |
0.316 |
|
| 2014 |
Kim DW, Zloza A, Broucek J, Schenkel JM, Ruby C, Samaha G, Kaufman HL. Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells. Journal of Translational Medicine. 12: 113. PMID 24885155 DOI: 10.1186/1479-5876-12-113 |
0.349 |
|
| 2014 |
Zloza A, Kim DW, Kim-Schulze S, Jagoda MC, Monsurro V, Marincola FM, Kaufman HL. Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses. Journal For Immunotherapy of Cancer. 2: 1. PMID 24829758 DOI: 10.1186/2051-1426-2-1 |
0.345 |
|
| 2014 |
Lu R, Wu S, Zhang Y, Xia Y, Huelsmann EJ, Lacek AT, Nabatiyan A, Richards MH, Narasipura SD, Lutgen V, Chen H, Kaufman HL, Chen D, Al-Harthi L, Zloza A, et al. HIV infection accelerates gastrointestinal tumor outgrowth in NSG-HuPBL mice. Aids Research and Human Retroviruses. 30: 677-84. PMID 24593860 DOI: 10.1089/Aid.2013.0289 |
0.657 |
|
| 2014 |
Rubinstein PG, Aboulafia DM, Zloza A. Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. Aids (London, England). 28: 453-65. PMID 24401642 DOI: 10.1097/Qad.0000000000000071 |
0.38 |
|
| 2014 |
Chesson CB, Huelsmann EJ, Lacek AT, Kohlhapp FJ, Webb MF, Nabatiyan A, Zloza A, Rudra JS. Antigenic peptide nanofibers elicit adjuvant-free CD8⁺ T cell responses. Vaccine. 32: 1174-80. PMID 24308959 DOI: 10.1016/J.Vaccine.2013.11.047 |
0.344 |
|
| 2014 |
Broucek J, Hughes T, Huelsmann E, Lusciks E, Hill G, Zayas J, Poshepny J, Ruby C, Kohlhapp F, Zloza A, Kaufman H. Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P97 |
0.434 |
|
| 2014 |
Lu R, Wu S, Zhang Y, Xia Y, Huelsmann EJ, Lacek AT, Nabatiyan AS, Richards MH, Narasipura S, Lutgen V, Chen H, Kaufman HL, Chen D, Al-Harthi L, Zloza A, et al. Tu1692 HIV Infection Accelerates Gastrointestinal Tumor Outgrowth in Humanized NSG-HuPBL Mice Gastroenterology. 146: S-820. DOI: 10.1016/S0016-5085(14)62969-3 |
0.657 |
|
| 2013 |
Mosenson JA, Zloza A, Nieland JD, Garrett-Mayer E, Eby JM, Huelsmann EJ, Kumar P, Denman CJ, Lacek AT, Kohlhapp FJ, Alamiri A, Hughes T, Bines SD, Kaufman HL, Overbeck A, et al. Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Science Translational Medicine. 5: 174ra28. PMID 23447019 DOI: 10.1126/Scitranslmed.3005127 |
0.362 |
|
| 2013 |
Broucek JR, Hughes T, Huelsmann EJ, Poshepny JL, Ruby CE, Zloza A, Kaufman HL. Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P70 |
0.363 |
|
| 2013 |
Zloza A, Broucek JR, Huelsmann EJ, Hughes T, Kaufman HL. Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P266 |
0.359 |
|
| 2013 |
Stonewall K, Quintero C, Zloza A, Kaufman H, Ruby C. The impact of age on a mitoxantrone-based tumor vaccine Journal For Immunotherapy of Cancer. 1: P234. DOI: 10.1186/2051-1426-1-S1-P234 |
0.361 |
|
| 2013 |
Huelsmann E, Broucek J, Lacek A, Lusciks E, Saba J, Nabatiyan A, Zloza A. PD-1 blockade reverses viral infection-induced loss of anti-tumor CD8+ T cell responses Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P156 |
0.464 |
|
| 2012 |
Kohlhapp FJ, Zloza A, O'Sullivan JA, Moore TV, Lacek AT, Jagoda MC, McCracken J, Cole DJ, Guevara-Patiño JA. CD8(+) T cells sabotage their own memory potential through IFN-γ-dependent modification of the IL-12/IL-15 receptor α axis on dendritic cells. Journal of Immunology (Baltimore, Md. : 1950). 188: 3639-47. PMID 22430740 DOI: 10.4049/Jimmunol.1101580 |
0.471 |
|
| 2012 |
Zloza A, Kohlhapp FJ, Lyons GE, Schenkel JM, Moore TV, Lacek AT, O'Sullivan JA, Varanasi V, Williams JW, Jagoda MC, Bellavance EC, Marzo AL, Thomas PG, Zafirova B, Poli? B, et al. NKG2D signaling on CD8⁺ T cells represses T-bet and rescues CD4-unhelped CD8⁺ T cell memory recall but not effector responses. Nature Medicine. 18: 422-8. PMID 22366950 DOI: 10.1038/Nm.2683 |
0.682 |
|
| 2012 |
Mosenson JA, Zloza A, Klarquist J, Barfuss AJ, Guevara-Patino JA, Poole IC. HSP70i is a critical component of the immune response leading to vitiligo. Pigment Cell & Melanoma Research. 25: 88-98. PMID 21978301 DOI: 10.1111/J.1755-148X.2011.00916.X |
0.344 |
|
| 2011 |
Zloza A, Lyons GE, Chlewicki LK, Kohlhapp FJ, O'Sullivan JA, Lacek AT, Moore TV, Jagoda MC, Kumar V, Guevara-Patiño JA. Engagement of NK receptor NKG2D, but not 2B4, results in self-reactive CD8+ T cells and autoimmune vitiligo. Autoimmunity. 44: 599-606. PMID 21913803 DOI: 10.3109/08916934.2011.593599 |
0.475 |
|
| 2011 |
O'Sullivan JA, Zloza A, Kohlhapp FJ, Moore TV, Lacek AT, Dulin NO, Guevara-Patiño JA. Priming with very low-affinity peptide ligands gives rise to CD8(+) T-cell effectors with enhanced function but with greater susceptibility to transforming growth factor (TGF)β-mediated suppression. Cancer Immunology, Immunotherapy : Cii. 60: 1543-51. PMID 21681376 DOI: 10.1007/S00262-011-1043-1 |
0.46 |
|
| 2011 |
Bellavance EC, Kohlhapp FJ, Zloza A, O'Sullivan JA, McCracken J, Jagoda MC, Lacek AT, Posner MC, Guevara-Patino JA. Development of tumor-infiltrating CD8+ T cell memory precursor effector cells and antimelanoma memory responses are the result of vaccination and TGF-β blockade during the perioperative period of tumor resection. Journal of Immunology (Baltimore, Md. : 1950). 186: 3309-16. PMID 21289306 DOI: 10.4049/Jimmunol.1002549 |
0.428 |
|
| 2011 |
Zloza A, Jagoda MC, Lyons GE, Graves MC, Kohlhapp FJ, O'Sullivan JA, Lacek AT, Nishimura MI, Guevara-Patiño JA. CD8 co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor-β (TGF-β)-mediated suppression. Cancer Immunology, Immunotherapy : Cii. 60: 291-7. PMID 21193909 DOI: 10.1007/S00262-010-0962-6 |
0.433 |
|
| 2010 |
Schenkel JM, Zloza A, Li W, Narasipura SD, Al-Harthi L. Beta-catenin signaling mediates CD4 expression on mature CD8+ T cells. Journal of Immunology (Baltimore, Md. : 1950). 185: 2013-9. PMID 20631314 DOI: 10.4049/Jimmunol.0902572 |
0.653 |
|
| 2009 |
Zloza A, Schenkel JM, Tenorio AR, Martinson JA, Jeziorczak PM, Al-Harthi L. Potent HIV-specific responses are enriched in a unique subset of CD8+ T cells that coexpresses CD4 on its surface. Blood. 114: 3841-53. PMID 19700667 DOI: 10.1182/Blood-2009-02-202481 |
0.689 |
|
| 2008 |
Kumar A, Zloza A, Moon RT, Watts J, Tenorio AR, Al-Harthi L. Active beta-catenin signaling is an inhibitory pathway for human immunodeficiency virus replication in peripheral blood mononuclear cells. Journal of Virology. 82: 2813-20. PMID 18199649 DOI: 10.1128/Jvi.02498-07 |
0.605 |
|
| 2006 |
Zloza A, Al-Harthi L. Multiple populations of T lymphocytes are distinguished by the level of CD4 and CD8 coexpression and require individual consideration. Journal of Leukocyte Biology. 79: 4-6. PMID 16380600 DOI: 10.1189/Jlb.0805455 |
0.657 |
|
| 2004 |
Managlia EZ, Carroll D, Zloza A, Al-Harthi L. Immune modulation of HIV replication: relevance to HIV immuno- and neuro-pathogenesis. Current Hiv Research. 2: 395-401. PMID 15544459 DOI: 10.2174/1570162043351020 |
0.734 |
|
| 2003 |
Zloza A, Sullivan YB, Connick E, Landay AL, Al-Harthi L. CD8+ T cells that express CD4 on their surface (CD4dimCD8bright T cells) recognize an antigen-specific target, are detected in vivo, and can be productively infected by T-tropic HIV. Blood. 102: 2156-64. PMID 12791668 DOI: 10.1182/Blood-2002-07-1972 |
0.733 |
|
| Show low-probability matches. |